Reuters |
'New Era' of Type 2 Diabetes Treatment as LEADER Unveiled?
Medscape NEW ORLEANS — Details of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results—A Long Term Evaluation (LEADER) trial of the glucose-lowering drug liraglutide (Victoza, Novo Nordisk), showing that it significantly … Novo diabetes drug cuts heart risks by less-than-hoped 13 percentageReuters Novo Nordisk Drug Cuts Diabetic Deaths, But Not Enough For Wall StreetInvestor’s Business Daily GLP-1 Drug Cuts Heart Risk in DiabetesMedPage Today The Diabetes Times –Bloomberg all 59 news articles » |
More details can be found at www.diabeteshowto.com
Discussion
Comments are disallowed for this post.
Comments are closed.